Pure Global
NCT06393517

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

A PHASE 1, OPEN-LABEL, RANDOMIZED, 5-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF IMMEDIATE-RELEASE AND MODIFIED-RELEASE FORMULATIONS OF PF-06954522 ADMINISTERED ORALLY TO HEALTHY ADULT PARTICIPANTS
Pfizer·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
PF-06954522 IR (Formulation 1)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Pfizer
Location
New Haven, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 30, 2024
End date
Jul 15, 2024
Enrollment
12 participants
Primary outcome

Area Under the Curve from time zero to extrapolated infinite time (AUCinf) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.,Maximum Observed Plasma Concentration (Cmax) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.

Summary

The purpose of this study is to compare three finished products of PF-06954522 in terms of
 the uptake into the blood stream.
 
 This study is seeking participants who are:
 
 - Healthy male or female participants aged 18 years or older.
 
 All participants in this study will receive PF-06954522 once by mouth. The participants may
 receive different tablets by mouth for PF-06954522.
 
 The study will compare experiences of people receiving three different products of
 PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for
 each product given.
 
 Participants will take part into the study for about 77 days. During this time participants
 will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06393517
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06393517 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.